Akkari Yassmine M N, Talkowski Michael E, Breman Amy M
Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
Department of Pathology, The Ohio State University, Columbus, Ohio, USA.
Prenat Diagn. 2025 Sep;45(10):1334-1342. doi: 10.1002/pd.6847. Epub 2025 Aug 1.
Cytogenetic technologies such as G-banding chromosome and FISH analyses have long been the gold standard diagnostic test in prenatal genetic testing. However, unbiased next-generation sequencing technologies such as fetal exome or genome sequencing (ES/GS) are becoming widely accessible and increasingly utilized, particularly for fetuses with structural anomalies. Emerging studies are now establishing increased diagnostic yields from molecular technologies, but there remains a lack of consensus as to whether ES/GS should replace cytogenetic technologies and targeted genepanel screening as first-line tests for all prenatal diagnoses. This report is a summary of the debate on this topic presented at the 28th International Conference on Prenatal Diagnosis and Fetal Therapy. Both expert debaters discussed the advantages and disadvantages.
诸如G带染色体分析和荧光原位杂交(FISH)分析等细胞遗传学技术长期以来一直是产前基因检测的金标准诊断测试。然而,诸如胎儿外显子组或基因组测序(ES/GS)等无偏差的新一代测序技术正变得广泛可用且越来越多地被使用,特别是对于有结构异常的胎儿。新兴研究目前正在证实分子技术的诊断率有所提高,但对于ES/GS是否应取代细胞遗传学技术和靶向基因panel筛查作为所有产前诊断的一线检测方法,仍缺乏共识。本报告是在第28届产前诊断与胎儿治疗国际会议上就该主题进行的辩论总结。两位专家辩论者都讨论了其优缺点。